Back to Report Store Home

Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • Published: Dec-2016
  • Report Code: GBIHC417MR
  • Report Format: pdf

Description

List of Tables

Table 1: Type 2 Diabetes Mellitus, Global, Related Indications of T2DM First-in-Class Products, 2016 49

Table 2: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 55

Table 3: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 55

Table 4: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 55

Table 5: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 55

Table 6: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 56

Table 7: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 57

Table 8: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 58

Table 9: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 58

Table 10: Type 2 Diabetes Mellitus, Global Pipeline Programs Targeting XXX, 2016 59

Table 11: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 60

Table 12: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 61

Table 13: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 61

Table 14: Type 2 Diabetes Mellitus, Global Pipeline Programs Targeting XXX, 2016 62

Table 15: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 62

Table 16: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 63

Table 17: Type 2 Diabetes Mellitus, Global, Key Features of XXX, 2016 63

Table 18: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting XXX, 2016 65

Table 19: Type 2 Diabetes Mellitus Market, Global, Key Features of XXX, 2016 65

Table 20: Type 2 Diabetes Market, Global, Pipeline Programs Targeting XXX, 2016 66

Table 21: Type 2 Diabetes Mellitus Market, Global, Key Features of XXX, 2016 66

Table 22: Type 2 Diabetes Mellitus, Global, Licensing Deals Valued Above $100m, 2006–2016 73

Table 23: Type 2 Diabetes Mellitus, Global, Co-development Deals Valued Above $100m, 2006–2016 78

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards